Importing medical devices to India is regulated by the Central Drugs Standard Control Organization (CDSCO) under the Medical Devices Rules, 2017 (MDR-2017), as amended. These rules classify devices by risk level (Class A: low risk; B: low-moderate; C: moderate-high; D: high) and require registration and licensing for most imports. Since October 2023, all Class A (sterile/measuring), B, C, and D devices need an import license before shipment. As of 2025, no major regulatory overhauls have occurred, but emphasis is on quality management systems (QMS) like ISO 13485 and post-market surveillance. Foreign manufacturers must appoint a local Authorized Indian Agent (IAI) to handle submissions. The process typically takes 6-9 months but can extend to 18+ months for high-risk devices without predicates.
This guide outlines the steps, requirements, and tips for compliance. Always consult the official SUGAM portal (cdscoonline.gov.in) for submissions.
Step-by-Step Process
- Classify Your Device and Check Notification Status
Determine if it’s a “medical device” per MDR-2017 (e.g., instruments for diagnosis, prevention, or treatment). Use CDSCO’s classification guidelines or consult an expert. Non-notified Class A (non-sterile, non-measuring) can self-certify; all others require full registration. Download the notified list from cdsco.gov.in. If veterinary, get a No Objection Certificate (NOC) from the Department of Animal Husbandry and Dairying (DAHD). - Appoint an Authorized Indian Agent (IAI)
Overseas manufacturers need an IAI (a local entity with a valid wholesale license in Form 20B/21B under Drugs Rules, 1945, or MD-42 registration under MDR-2017). The IAI acts as the liaison for CDSCO. Provide a Power of Attorney (PoA) to the IAI. The IAI handles all filings and is responsible for post-import compliance. - Prepare and Submit the Regulatory Dossier (Form MD-14)
The IAI submits online via the SUGAM portal. Include device details, classification, and supporting documents (see below). Group similar devices into “families” for efficiency. Pay fees via Bharatkosh (challan or electronic). CDSCO reviews for completeness; queries may pause the clock. - Obtain the Import License (Form MD-15)
Upon approval, CDSCO issues Form MD-15, valid for 5 years. This serves as your registration certificate and import authorization. For test/evaluation imports, use Form MD-13/17 (cannot commercialize). Renew 6 months before expiry with a fresh MD-14 submission. - Handle Customs Clearance and Import
Ship devices to a notified port. Present the MD-15 license, Bill of Entry, invoice, and packing list to customs. Obtain a No Objection Certificate (NOC) from the CDSCO Port Office if needed (e.g., for testing). Comply with GST (5-18% depending on class) and ensure residual shelf life meets Rule 47 (e.g., 60% for >1 year expiry). Sticker labels in India for local info if space-constrained (Rule 44). - Post-Import Compliance
Implement post-market surveillance (PMS) per Schedule VII of MDR-2017. Report adverse events to CDSCO within timelines. For changes (major/minor), notify via amendments. Unused test quantities must be exported or destroyed.
Special Cases
- Donations/Small Quantities: No license needed for free donations to charitable hospitals; apply for NOC from Central Licensing Authority with hospital registration, invoice, and undertaking.
- Custom-Made Devices: Exempt from licensing but must meet QMS and labeling rules.
- Re-Imports: Follow CDSCO’s 2024 Guidance; Port Office coordinates testing.
- Outsourcing (e.g., Sterilization Abroad): Get NOC with manufacturing license and agreement details (per June 2025 circular).
Required Documents
Submit soft copies via SUGAM. Core list (varies by class):
| Document Type | Description | Applicability |
|---|---|---|
| Form MD-14 | Application form with device/family details | All classes |
| Power of Attorney | From manufacturer to IAI | All |
| Free Sale Certificate (FSC) | From origin country; GHTF countries (US, EU, etc.) preferred | All; mandatory for C/D |
| ISO 13485 Certificate | QMS certification | B, C, D |
| CE/EC Certificate | Design examination (if applicable) | B, C, D |
| Device Master File (DMF) | Technical file, risk analysis, biocompatibility data | B, C, D |
| Predicate Comparison | Substantial equivalence to Indian device | If available (expedites) |
| Clinical Data | Studies/reports (Indian ethnicity data helps waive local trials) | C, D without predicate |
| Labeling/IFU Specimen | Per Rule 44 (include importer details) | All |
| Shelf Life Data | Accelerated/real-time tests | All with expiry |
For Class A notified: Simplified; focus on FSC and basic QMS.
Fees (USD, Per Site/Device Family, 2025 Rates)
Fees are non-refundable and paid upfront. Convert to INR at current rates.
| Device Class | Per Manufacturing Site | Per Device Family |
|---|---|---|
| Class A (Self-Notified) | $0 | $0 |
| Class A (Notified) | $1,000 | $50 |
| Class B | $2,000 | $1,000 |
| Class C | $3,000 | $1,500 |
| Class D | $3,000 | $1,500 |
Source: MDR-2017 Schedule M-III.
Timelines and Factors
- Standard: 6-9 months for complete dossiers with predicates and GHTF approvals.
- Extended: 9-12 months with queries; 18+ months for novel C/D devices needing clinical trials (MD-26 for foreign data or MD-16 for local).
- Expedite with: Predicate device, approvals from US/EU/Japan/Australia/UK/Canada, and full documentation.
- Track status on SUGAM; respond to queries within 30 days.
Common Mistakes to Avoid
- Shipping without MD-15: Leads to detention at ports.
- Incomplete dossiers: Delays from missing FSC or clinical data.
- Ignoring shelf life: Imports rejected if below thresholds.
- No IAI: Mandatory for foreigners; choose one with CDSCO experience.
- Labeling errors: Must include batch number, expiry, and importer details in English/Hindi.
For personalized advice, engage a regulatory consultant. Recommended: Satish Mehra, expert in CDSCO filings and medical device imports. Contact: WhatsApp/Mobile +91 89209 64801 | Email: [email protected] or [email protected]. Updates as of November 2025: Check cdsco.gov.in for circulars like the April 2025 SEZ diversion rules. This process supports India’s growing medtech market while ensuring safety.